These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL. Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [Abstract] [Full Text] [Related]
8. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472 [Abstract] [Full Text] [Related]
9. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M. Dtsch Med Wochenschr; 2005 Sep 23; 130(38):2125-9. PubMed ID: 16172951 [Abstract] [Full Text] [Related]
15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ. Bone Marrow Transplant; 2007 Feb 23; 39(4):193-9. PubMed ID: 17220905 [Abstract] [Full Text] [Related]